- Evidence Level: Strong for MS/SCI spasticity (Sativex RCTs); Moderate for neuropathic muscle pain; Low for exercise-induced spasm and fibromyalgia
- Best Cannabinoids: THC (primary antispastic via CB1); 1:1 CBD:THC (Sativex ratio, strongest RCT evidence); CBD alone for exercise-induced spasm
- Recommended Methods: Oromucosal spray (Sativex); sublingual tincture; topical for localised spasm
- Onset/Duration: Oromucosal/sublingual: 20–40 min onset, 4–6 h duration; oral capsule: 60–120 min, 6–8 h
- Key Cautions: THC psychoactivity and tolerance; titration over 2+ weeks required; magnesium interaction (additive); do not abruptly discontinue Sativex
How Cannabis Interacts with Muscle Spasm Physiology
Muscle spasms and spasticity arise from disrupted inhibitory control of motor neurons. In healthy physiology, spinal cord GABAergic interneurons and glycinergic neurons tonically inhibit alpha motor neurons — preventing excessive or involuntary firing. When this inhibitory control is disrupted (upper motor neuron lesions in MS or SCI, or acute overexcitation from injury/fatigue), muscles contract involuntarily.
The endocannabinoid system intervenes at multiple levels of this circuit:
CB1 Receptors on Spinal Interneurons (Hohmann 1999): CB1 receptors are expressed on GABAergic interneurons throughout the spinal cord dorsal and ventral horn. Cannabinoid agonism at these receptors does not directly inhibit motor neurons — rather, it modulates the inhibitory interneuron networks. Presynaptic CB1 activation reduces glutamate release from excitatory terminals, shifting the excitatory/inhibitory balance toward inhibition and reducing the hyperexcitability that drives spasm.
Glycine Receptor Potentiation: CBD potentiates alpha-1 and alpha-3 glycine receptors — the primary inhibitory neurotransmitter receptors in the spinal cord ventral horn. Glycine receptor activation directly hyperpolarises motor neurons, reducing firing frequency. This mechanism (Xiong 2011, Nature Chemical Biology) is CB1-independent and provides a parallel antispastic pathway, explaining why CBD enhances THC’s effects even beyond simple additive action.
Peripheral CB1/CB2 in Muscle and Skin: Cannabinoid receptors are expressed in muscle spindles (CB1), skin keratinocytes (CB1, CB2), and peripheral sensory nerves. Topical cannabinoid application activates these peripheral receptors, reducing local pain signals and muscle tension without systemic psychoactivity.
Types of Muscle Spasm: Different Mechanisms, Different Cannabis Approaches
| Spasm Type | Primary Mechanism | Examples | Best Cannabis Approach | Evidence Quality |
|---|---|---|---|---|
| Spasticity (UMN lesion) | Upper motor neuron damage → loss of inhibitory interneuron control → velocity-dependent resistance to passive movement | Multiple sclerosis, spinal cord injury, stroke | Sativex (nabiximols) 1:1 THC:CBD; sublingual tincture | Strong (multiple RCTs) |
| Nocturnal leg cramps | Electrolyte imbalance, reduced blood flow, nerve fatigue; involuntary calf/foot spasm during sleep | Idiopathic leg cramps, pregnancy cramps, diabetic cramps | Low-dose THC (5 mg) or CBN capsule before bed; high-CBD tincture | Low (anecdotal) |
| Exercise-induced spasm | Lactic acid accumulation, electrolyte depletion, neuromuscular fatigue, DOMS | Athletic cramps, DOMS, fibromyalgia flare post-exercise | CBD 300 mg pre-exercise; topical CBD post-exercise | Low-Moderate (McCartney 2020) |
| Fibromyalgia-associated spasm | Central sensitisation; disrupted descending pain inhibition; substance P excess | Fibromyalgia widespread muscle pain and spasm | High-CBD with low THC; emphasis on sleep improvement; full-spectrum products | Low (observational) |
| Back muscle spasm | Acute muscle guarding response to injury/inflammation; reflex spasm loop | Acute back spasm, sciatica-related spasm | Topical cannabinoid + oral 1:1 tincture; anti-inflammatory terpenes (caryophyllene) | Low |
Cannabinoids and Their Roles in Spasm
| Cannabinoid | Mechanism | Antispastic Action | Relative Efficacy | Notes |
|---|---|---|---|---|
| THC | CB1 agonism on spinal interneurons; presynaptic glutamate reduction; hypothalamic thermoregulation | Primary antispastic — reduces velocity-dependent resistance, frequency of spasm episodes | High (acutely) | Psychoactivity; tolerance builds; most effective at moderate doses |
| CBD | Glycine receptor potentiation; CB1 negative allosteric modulation; anti-neuroinflammatory (CB2/NF-kB) | Enhances THC antispastic effect; independent antispastic via glycine pathway; CB1-independent | Moderate alone; High in combination | Non-psychoactive; essential component of Sativex ratio |
| 1:1 THC:CBD | Combined CB1 agonism + glycine potentiation + CB1 allosteric modulation | Superior to either alone in RCT evidence; the pharmacological basis of Sativex | Very High | Gold-standard combination for spasticity |
| CBG | Alpha-2 adrenoceptor agonism; GABA reuptake inhibition | GABA reuptake inhibition increases inhibitory tone; muscle relaxant potential | Low (preclinical) | Limited human evidence; preclinical GABA mechanism compelling |
| Beta-Caryophyllene | CB2 agonism; NF-kB anti-inflammatory | Reduces neuroinflammation contributing to central sensitisation in fibromyalgia/SCI | Low (supportive) | Endogenous in high-caryophyllene strains; OTC supplement available |
| myrcene | GABA-A modulation; muscle relaxant (Do Vale 2002) | Enhances sedation and muscle relaxation; contributes to indica-strain muscle relaxant reputation | Low-Moderate (supportive) | High-myrcene strains: Granddaddy Purple, OG Kush, Blue Dream |
Clinical Evidence: Sativex RCT Data
| Study | Design | Population | Key Findings | Reference |
|---|---|---|---|---|
| Novotna et al. (2011) | Phase 3 RCT (pivotal trial) | MS spasticity (n=241, treatment-resistant) | Nabiximols significantly reduced NRS spasticity score vs. placebo (p<0.0001); 35% of patients were “responders” (≥30% improvement); caregiver-assessed benefit confirmed | Lancet Neurol 10(6):521-9 — PMID 21514916 |
| Wade et al. (2004) | Phase 2 RCT | MS symptoms (n=160, multiple MS symptoms) | Cannabis extract (CBD:THC) significantly improved spasticity (p=0.001), pain (p=0.003), bladder dysfunction vs. placebo; 14% withdrew due to adverse events (dizziness, nausea) | Mult Scler 10(4):434-41 — PMID 15327040 |
| Collin et al. (2010) | RCT | MS spasticity (n=189) | Nabiximols produced clinically meaningful improvement in spasticity NRS scores; improved sleep quality as secondary endpoint; well-tolerated with titration | Eur J Neurol 17(9):1143-52 — PMID 20345958 |
| Collin et al. (2007) | RCT | MS spasticity (n=189) | 28% of nabiximols group achieved ≥30% improvement vs. 16% placebo (p=0.035); responder analysis supports clinical use in treatment-resistant spasticity | Eur J Neurol 14(3):290-6 — PMID 17355549 |
| McCartney et al. (2020) | Systematic review | CBD and exercise recovery | CBD 300 mg pre-exercise reduced exercise-induced muscle damage markers and perceived soreness; anti-inflammatory and anxiolytic properties relevant to exercise recovery | Int J Sport Nutr Exerc Metab 30(5):363-372 — PMID 32580350 |
| Xiong et al. (2011) | Preclinical mechanistic | Rodent spinal cord | CBD potentiates alpha-1 and alpha-3 glycine receptors at nanomolar concentrations; mechanism independent of CB1/CB2; direct motor neuron hyperpolarisation; explains CBD antispastic action | Nature Chem Biol 8(5):427-36 — PMID 22466420 |
Sativex Dosing Protocol
Sativex (nabiximols) is the most rigorously studied cannabinoid preparation for spasticity. Each actuation delivers 2.7 mg THC and 2.5 mg CBD. The titration protocol used in RCTs:
| Week | Morning Sprays | Evening Sprays | Total THC/CBD per Day | Notes |
|---|---|---|---|---|
| Week 1 | 0 | 1 | 2.7 mg THC / 2.5 mg CBD | Assess tolerability; watch for dizziness, dry mouth, fatigue |
| Week 2 | 0 | 2 | 5.4 mg THC / 5.0 mg CBD | Increase only if well-tolerated; reassess spasticity score |
| Week 3 | 1 | 2 | 8.1 mg THC / 7.5 mg CBD | Add morning dose for daytime spasm coverage |
| Week 4 | 2 | 2–4 | 10.8–16.2 mg THC | Maximum 12 sprays/day (32.4 mg THC / 30 mg CBD) — rarely needed |
| Maintenance | Individual | Individual | Patient-specific minimum effective dose | Responder assessment at 4 weeks — discontinue if <30% NRS improvement |
Responder assessment: Patients who achieve ≥30% reduction in NRS spasticity score at 4 weeks are classified as responders and continue. Non-responders should discontinue Sativex. This approach is mandated in UK NHS guidelines and most European formularies.
General Dosing Guide
| Indication | Starting Dose | Effective Range | Timing | Method | Notes |
|---|---|---|---|---|---|
| MS/SCI spasticity | 2.7 mg THC + 2.5 mg CBD (1 Sativex spray) | 8–27 mg THC + 7.5–25 mg CBD/day | Evening start; titrate over 2 weeks | Oromucosal spray (Sativex) or sublingual tincture | Responder assessment at 4 weeks essential |
| Nocturnal leg cramps | 5 mg THC or 5 mg CBN | 5–10 mg THC or CBN | 30–60 min before bed | Capsule or sublingual | CBN preferred if psychoactivity unwanted; check magnesium levels |
| Exercise-induced spasm | 50–100 mg CBD | 300 mg CBD pre-exercise | 1–2 h before exercise | Oral capsule | Topical CBD post-exercise for localised DOMS |
| Fibromyalgia spasm | 5 mg 1:1 tincture (morning) | 10–20 mg 1:1 per dose, 2x daily | Morning + evening | Sublingual tincture | Sleep improvement often drives most benefit; high-CBD emphasis |
| Localised back spasm | Topical: 50–100 mg CBD cream | 50–250 mg CBD topical + 5 mg THC oral | Apply topical 3x daily; oral at night | Topical cream + oral supplement | Transdermal absorption limited; high-concentration topicals required |
Delivery Methods Comparison
| Method | Onset | Duration | Bioavailability | Best For | Key Consideration |
|---|---|---|---|---|---|
| Oromucosal spray (Sativex) | 15–40 min | 4–6 h | ~12–20% | MS/SCI spasticity (regulated product) | Standardised dose; apply to gum/inner cheek, not under tongue |
| Sublingual tincture (1:1) | 15–45 min | 4–6 h | 13–19% | Spasticity, nocturnal cramps, daytime spasm | Hold 60–90 sec; variable bioavailability between products |
| Oral capsule | 60–120 min | 6–8 h | 4–20% | Chronic spasticity (MS/SCI); fibromyalgia; exercise recovery | Take with fat-containing meal for max absorption; first-pass 11-OH-THC formation |
| Topical cream/balm | 15–45 min (local) | 2–4 h | Very low systemic (<1%) | Localised spasm, DOMS, back spasm, nocturnal calf cramps | No psychoactivity; requires high cannabinoid concentration (100+ mg/application) |
| Vaporiser | 5–10 min | 2–3 h | 25–35% | Rapid relief of acute spasm episode | Short duration; adequate for acute episodes; not ideal for chronic management |
| Transdermal patch | 2–4 h (slow) | 8–12 h | Variable (formulation-dependent) | Continuous baseline coverage for chronic spasticity | Emerging technology; limited standardised products; promising for overnight coverage |
Strain Recommendations for Muscle Spasms
| Strain | Type | THC / CBD | Key Terpenes | Spasm Profile |
|---|---|---|---|---|
| OG Kush | Hybrid (indica-leaning) | 19–26% / <1% | Myrcene, Caryophyllene, limonene | Classic muscle relaxant; reliable for evening spasticity |
| Granddaddy Purple | Indica | 17–23% / <1% | Myrcene, Caryophyllene, linalool | Heavy body relaxation; nocturnal leg cramps and spasticity |
| Harlequin | Sativa-hybrid (high CBD) | 4–7% / 8–16% | Myrcene, Caryophyllene, pinene | Daytime spasticity management; clear-headed; 1:2 THC:CBD equivalent |
| Cannatonic | Hybrid (high CBD) | 4–7% / 6–17% | Myrcene, Pinene, Caryophyllene | MS spasticity; non-psychoactive at CBD-dominant phenotype; daytime |
| Blue Dream | Sativa-hybrid | 17–24% / <1% | Myrcene, Caryophyllene, Pinene | Moderate muscle relaxation with functional clarity; daytime spasm |
| Northern Lights | Indica | 16–21% / <1% | Myrcene, Caryophyllene, Ocimene | Reliable evening muscle relaxant; well-suited to nocturnal spasm management |
| ACDC (CBD-dominant) | Hybrid | <1% / 14–20% | Myrcene, Pinene, Ocimene | Exercise-induced spasm and DOMS; no psychoactivity; glycine pathway |
Topical Cannabinoids for Localised Spasm
For localised muscle spasm — such as back spasm, calf cramps, or post-exercise soreness affecting a specific region — topical cannabinoid formulations offer targeted relief without systemic psychoactivity.
Transdermal cannabinoid penetration relies on the lipophilicity of cannabinoids (logP ~7 for THC, ~6 for CBD), but the skin’s stratum corneum presents a significant barrier. Effective topical products require:
- High cannabinoid concentration (typically 250–2500 mg per container)
- Penetration enhancers: liposomes, nanoemulsions, or chemical enhancers (DMSO, menthol, propylene glycol)
- Carrier: lipophilic base (coconut oil, shea butter) or transdermal gel
CB1 and CB2 receptors are present in skin keratinocytes, dermal fibroblasts, hair follicles, and sensory nerve fibres. Local activation reduces substance P and CGRP (pain neuropeptides), decreases mast cell degranulation, and reduces peripheral sensitisation contributing to referred muscle pain.
Magnesium Interaction Note
Many patients with chronic muscle cramps and spasticity supplement with magnesium (glycinate, malate, or citrate forms). Magnesium acts as a natural NMDA receptor antagonist and calcium channel regulator — complementary to cannabinoid mechanisms at the spinal cord level. The combination of magnesium 300–400 mg/day with cannabinoids likely produces an additive antispastic effect. No adverse interaction has been documented. Patients on both should monitor for excessive muscle weakness (rare at therapeutic doses).
Risks and Contraindications
| Risk | Details | Spasm-Specific Context | Management |
|---|---|---|---|
| Psychoactivity impairment | THC impairs cognition, coordination, driving; dose-dependent | MS/SCI patients may be already motorically impaired; adds fall risk | Evening dosing preferred; CBD:THC ratio minimises psychoactivity; driver assessment |
| Tolerance to antispastic effect | CB1 downregulation with chronic use; Sativex trials showed no significant tolerance over 12 months in responder populations, but dose creep possible | Long-term spasticity management requires monitoring | Maintain minimum effective dose; reassess quarterly; cycling if needed |
| Withdrawal spasm worsening | Abrupt cannabinoid cessation may temporarily worsen spasticity | Documented in Sativex trials; typically resolves in 1–2 weeks | Gradual taper if discontinuing; alternative antispastics ready (baclofen, tizanidine) |
| Falls | Cannabis impairs balance and reaction time via cerebellar CB1 | MS and SCI patients already have elevated fall risk; cannabis adds to this | Dose titration protocol; assess transfer safety; use during periods of low fall-risk activity |
| Cardiovascular (tachycardia) | THC increases heart rate by 20–50 bpm (transient, dose-dependent) | MS patients may have autonomic dysfunction; cardiac comorbidities common | Cardiovascular screen before use; avoid in recent cardiac history |
| Contraindication: pregnancy | Cannabinoids cross placental barrier; fetal harm documented | Absolute contraindication | Avoid cannabis; baclofen or physiotherapy for spasticity in pregnancy |
| Contraindication: severe hepatic impairment | CBD inhibits multiple CYP450 enzymes; THC hepatically metabolised | Liver disease patients have reduced cannabinoid clearance; toxicity risk | Dose reduction and hepatic monitoring required; consult specialist |
Drug Interactions
| Medication | Interaction | Risk Level | Clinical Action |
|---|---|---|---|
| Baclofen (GABA-B agonist) | Additive CNS depression; both reduce spinal motor neuron excitability; enhanced antispastic effect and sedation | Moderate | Potential for baclofen dose reduction with cannabis; monitor sedation and weakness; avoid abrupt baclofen withdrawal |
| Tizanidine (alpha-2 agonist) | Additive CNS and cardiovascular depression; CBD inhibits CYP1A2 (tizanidine metabolism) → elevated plasma levels | High | Avoid combination or use with specialist guidance; tizanidine dose reduction likely required; monitor BP |
| Benzodiazepines (diazepam, clonazepam) | Additive GABA-A and CNS depression; significantly increased sedation and respiratory depression risk | High | Strong caution; dose reduction of benzo advised; do not combine without medical oversight |
| Dantrolene (direct-acting muscle relaxant) | Additive muscle weakness; both reduce muscle contraction strength | Moderate | Monitor for excessive weakness; hepatotoxicity with dantrolene not affected by cannabis |
| Warfarin | CBD inhibits CYP2C9 → increased INR → bleeding risk | High | INR monitoring mandatory; warfarin dose reduction likely needed |
| Magnesium supplements | Additive antispastic effect via NMDA + cannabinoid CB1 pathways | Low (beneficial) | Generally safe combination; monitor for excessive muscle weakness at high doses of both |
| Interferon-beta (MS disease-modifying) | No established pharmacokinetic interaction; CBD hepatic enzyme considerations theoretical at high doses | Low | Monitor liver function if combining high-dose CBD with hepatically-processed DMDs |
| Alcohol | Additive CNS depression; synergistic impairment of coordination and motor control | High | Avoid concurrent use; especially dangerous with existing motor impairment (MS/SCI) |
This content is for educational purposes only and does not constitute medical advice. Consult a healthcare professional before using cannabis for any medical condition.
Frequently Asked Questions
Does cannabis help with muscle spasms?
Yes, with strong evidence particularly for spasticity in multiple sclerosis (MS) and spinal cord injury (SCI). Nabiximols (Sativex), a 1:1 CBD:THC oromucosal spray, is approved in over 25 countries for MS spasticity based on multiple RCTs including the Novotna 2011 Lancet Neurology trial (n=241). Spinal CB1 receptors on GABAergic interneurons are the primary therapeutic target.
What is Sativex and how is it used for spasticity?
Sativex (nabiximols) is an oromucosal spray containing 2.7 mg THC and 2.5 mg CBD per spray, standardised from whole-plant cannabis extract. It is approved in 25+ countries for MS spasticity. Dosing begins at 1 spray per day, titrated over 2 weeks to maximum 12 sprays/day. The 1:1 THC:CBD ratio is superior to either alone — THC provides the primary antispastic effect while CBD modulates CB1 and reduces psychoactivity.
Can cannabis help exercise-induced muscle cramps?
Evidence is emerging. CBD 300 mg pre-exercise has shown promise in reducing exercise-induced muscle damage markers and perceived soreness (McCartney 2020 review). The CB1 mechanism on spinal interneurons reduces centrally-mediated muscle tension, while topical cannabinoids may address localised spasm through peripheral CB1 and CB2 receptors in skin and muscle.
Is THC or CBD more effective for muscle spasms?
THC is more effective acutely for muscle spasm reduction via CB1 agonism on spinal GABAergic interneurons. However, the 1:1 THC:CBD combination (as in Sativex) is superior to either cannabinoid alone in RCT evidence. CBD enhances the antispastic effect through CB1 negative allosteric modulation, glycine receptor potentiation, and reduction of neuroinflammation.
What cannabis products work best for MS spasticity?
Nabiximols (Sativex) has the strongest evidence for MS spasticity. Where not available, a 1:1 CBD:THC sublingual tincture or oromucosal spray is the closest equivalent. Start at 1–2 sprays/day and titrate carefully. Oral capsules provide longer-duration coverage for chronic spasticity. Topical cannabinoid preparations may offer localised relief with minimal systemic effects.